公开(公告)号：US20130266586A1

公开(公告)日：2013-10-10

申请号：US13841485

申请日：2013-03-15

申请人： University of Zürich

发明人： Roger NITSCH ,  Christoph Hock ,  Christoph Esslinger ,  Marlen Knobloch ,  Kathrin Tissot ,  Jan Grimm

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/52

摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。

公开(公告)号：US20130266514A1

公开(公告)日：2013-10-10

申请号：US13838526

申请日：2013-03-15

申请人： UNIVERSITY OF ZÜRICH

发明人： Roger NITSCH ,  Christoph Hock ,  Christoph Esslinger ,  Marlen Knobloch ,  Kathrin Tissot ,  Jan Grimm

IPC分类号： C07K16/18 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/52

摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

公开(公告)号：US20130216555A1

公开(公告)日：2013-08-22

申请号：US13717152

申请日：2012-12-17

申请人： University of Zürich

发明人： Roger NITSCH ,  Christoph HOCK ,  Christoph ESSLINGER ,  Marlen KNOBLOCH ,  Kathrin TISSOT ,  Jan GRIMM

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/52

摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.